Roche Zenapax/CellCept combo trial to seek superiority to cyclosporine, PDL says.
Executive Summary
ROCHE CELLCEPT/ZENAPAX STUDY BEING TOUTED AS "CYCLOSPORINE ELIMINATION" TRIAL, Zenapax innovator Protein Design Labs President Jon Saxe told analysts at a Paine Webber meeting in New York June 4. Roche has "initiated very recently a study of CellCept [mycophenylate mofetil] and Zenapax [dacliximab] versus cyclosporine with the thought that you could replace cyclosporine with this combination, get at least a result with far better patient safety" without the nephrotoxicity of cyclosporine.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth